文档介绍：***急性淋巴细胞白血病的治疗ALL化学治疗诱导治疗自发缓解VCR + Pred(VP)诱导,CR 36 – 67%VCR + DNR + Pred(VDP)诱导,CR 70 – 85%VCR + DNR + L-Asp + Pred (VDLP)—缓解期延长VCR + DNR + CTX + Pred (VDCP)缓解后治疗T-ALL :大剂量CTX冲击+ Ara-C成熟B-ALL:短疗程诱导及强化治疗中枢系统白血病的预防及治疗Remission Induction Regimens And Postremission Therapy for ALL No. of CNS Survival Reference patients Induction Consolidation Maintenance Prophylaxis CR% Med(mo) Blood 368 V, P, D, Cy, Dex, V, Dox, Cy 6-MP, MTX MTX, XRT 74 2871:123, 1988Ara-c, 6-MP Ara-C, TGBlood 168 V, P, Dox, Cy Ara-C, MTX, TG V, P, Dox, 6-MP MTX 68 18 73:87, 1989V, P, A, Cy MTX, ActD, Cy BCNUBlood 109 V, P, A, D V, P, A, D 6-MP, MTX MTX, XRT 88 28 78:2814, 1991Ara-c, VM26, MTX Leukemia 541 V, P, D, A V, P, Mito; 6-MP, MTX MTX 80 NR 6:182, 1992? Cy V, Dex, MTX; VM26, Ara-CBlood 197 V, P, A, D, Cy Cy, Ara-c, 6-MP, V 6-MP, MTX MTX, XRT 85 3685:78:2814, 1995 A, Dox, Dex, TG V, P Blood 128 Cy, V, Dox, DexMTX, Ara-C 6-MP, MTX, V, P MTX, Ara-C 91 3686:173a, 1995Group Year n (pts) Age* Induction Consolidation Maintenance CR LFSStudies with > 500 patientsGMALL 02/84 1993 562 28 V,P,A,D,C,AC,M,MP V,DX,AD,AC,C,TG,VM MP,M 75% 39%at7yFGTALL 1993 581 33 V,P,D/R,C [AD,AC]